Assisting Cancer Patients- Clay Siegall

Several organizations have come up to deal with cancer, and one of these companies which have been in existence for an extended period now is Seattle Genetics. Recently the Chief Executive Officer of Seattle Genetics Clay Siegall was speaking about the company’s innovation and its advancement in cancer therapy. The fact that its prices have been tripling over five years, it clearly shows the growth of the enterprise.

Dr. Clay Siegall has been very passionate about cancer therapy and has been making continuous efforts to improve the lives of cancer patients. Clay Siegall began his career in biomedical studies. Currently, he is Chairman and the Chief Executive Officer of Settle Genetics, a position he has held since 2002. Clay Siegall is the co-founder of the medical organization which was established in 1998. Since its foundation, Clay has been working effortlessly to take the firm into greater levels and realize revolutionary therapies for cancer patients.

Dr. Clay Siegall earned his Ph.D. in Genetics from George Washington University, and since then he has made several accomplishments in the medical and research sector. Before co-founding Seattle, he has served in several organization including; Bristol-Myers Squibb Pharmaceutical Research Institute where he began his career. Clay is a very determined man, and his efforts led to him climbing the career ladder to the position of a Principal Scientist before becoming a member of National Cancer Institute. His vast experience in the institutions gave him an opportunity to establish Seattle Genetics.

Clay Siegall’s accomplishments have been a commitment to concentrate on relevant research and being industrious on the execution on the most significant research developments. His hard work has been led by the desire to assist cancer patients. Mr. Clay’s passion for helping cancer patients has helped him take the company to a high level regarding research advancement. Under his tenure, the pharmaceutical organization has been able to develop its first Antibody Drug Conjugates (ADCs) including ADCETRIS which was approved by FDA in 2011. Since its development, the drug has been expanding its international impact, and it is now available in more than 60 nations world over.

Dr. Clay Siegall has been a leader in the growth of cancer therapies and has demonstrated exemplary leadership skills throughout his career. Clay was recognized by the University of Maryland as an alumnus of the year in computer, mathematics, and natural science in2013.